Business · 03/04/2026Updated: 10/16/2026 · 1 min read
FDA Determines Regulatory Review Period for EMRELIS Patent Extension
Summary
The FDA has determined the regulatory review period for EMRELIS, a human biological product patent extension, following USPTO submissions.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →